Abstract
The global dengue disease burden is estimated to affect about 400 million people with about a quarter manifesting clinically. Recently, the first vaccine CYDTDV (Dengvaxia) was recommended and licensed for use in individuals >9years of age based on findings from clinical trials; while the highest mortality is seen in children less that 9years of age. The vaccine was also recommended in settings with high sero-prevalence (>=70%) of dengue disease; with recommendations made for a pre-vaccination screening. This paper analyses the determinants and enablers for dengue vaccination needed to control the rising dengue epidemic, if maximizing public health impact remains imperative.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
